
No Serious Adverse Events (SAEs)
Strong Immune Response
Dual Mode of Action
Ongoing UK Phase 1 clinical trial with strong preliminary data
Our lead therapeutic agent, OVM-200, is in clinical trials in the UK. It is being used at leading hospitals to treat patients with advanced Non small cell lung cancer, ovarian cancer and prostate cancer. Initial results show excellent safety and a very strong immune response for both T-cells and antibodies – the dual mode of action.
Our Edge - Recombinant Overlapping Peptides (ROPs):
Our Edge - Recombinant Overlapping Peptides (ROPs):

Excellent safety profile
Strong immune response
Dual mode of action
Our vision for cancer therapeutics:-
with our unique ROP platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to many cancers, and available to as many patients as possible